我院2013年门诊口服降糖药临床应用分析

目的：对我院2013年门诊口服降糖药临床应用情况及趋势作出客观评价。方法：统计我院2013年门诊口服降糖药的销售金额、用药频度（DDDs）等，进行回顾性分析。结果：我院2013年口服降糖药销售金额排序前3位的是瑞格列奈片、阿卡波糖、格列吡嗪；DDDs排序前3位是格列吡嗪、格列齐特缓释片、格列苯脲片；日均费用前3位为格列苯脲片、格列吡嗪片、格列齐特缓释片。结论：我院口服降糖药使用较合理，糖苷酶抑制剂阿卡波糖、磺脲类药物的格列齐特因其疗效好、不良反应较少等居主导地位。

Application of oral hypoglycemic agent in Our Hospital in 2013

Objective：To make out the current situation and trend of oral hypoglycemic agent used in hospital and to make objective evaluation. Methods：The use of oral hypoglycemic agent in our hospital in 2013 was analyzed retrospectively in respect of consumption sum, DDDs .RESULTS：The top 3 oral hypoglycemic agent of consumption sum were Repaglinide, Acarbose and Glipizide.The top 3 oral hypoglycemic agent in respect of DDDs were Glipizide, Gliclazide Sustained-release Tablets and Glibenclamide. DDDc of Glibenclamide Glipizide and Gliclazide Sustained-release Tablets were the top 3.Conclusion：The use of oral hypoglycemic agent used in our hospital is rational on the whole, Acarbose of Glycosidase inhibitors and Gliclazide of Sulfonylureas are the most common because their good effects and few adverse reactions.